Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum Innovations - an infectious disease liquid biopsy diagnostics subsidiary and its newly established exclusive in-licensing arrangements with Accelerate Technologies Pte Ltd (“Accelerate Technologies”), commercialization arm of the Singapore’s Agency for Science, Technology and Research (“A*STAR”), to co-develop novel molecular-based rapid pathogen identification and detection diagnostics (“RPIDD”) technology. Aptorum Innovations, intends to target the global molecular diagnostics market estimated to reach USD$13.8billion in market size by 2025, of which 60% is estimated to be attributable to the infectious disease segment1, with its next-generation RPIDD technology.
The RPIDD technology was initiated and currently under development at A*STAR. The core objectives of RPIDD are to rapidly and accurately identify and detect existing or emerging unknown pathogens (including DNA/RNA-based viruses such as coronavirus, antibiotic-resistant bacteria, fungi, etc.), in a cost-effective, unbiased and broad-spectrum manner, through liquid biopsy (patients’ blood samples and is potentially adaptable for other sample types), genome sequencing and artificial intelligence driven software analytics. A key objective is also to develop RPIDD to leverage existing and emerging Next-Generation Sequencing platforms for pathogenic genome sequencing analysis.
Aptorum Innovations Pte Ltd (“Aptorum Innovations”), a subsidiary of Aptorum Group, is the exclusive licensee and commercializing party of the technology being developed in close cooperation with A*STAR and licensed by Accelerate Technologies. Subject to further validation and optimization of the RPIDD technology, Aptorum Group intends to open its initial series of RPIDD-driven infectious disease liquid biopsy diagnostics laboratories over the course of the next two years, with at least one flagship location in Singapore in collaboration with local hospitals and clinics; other targeted follow-on locations include the United States, European Union and the United Kingdom. Through A*STAR, the technology is currently undergoing product optimization at its Diagnostics Development Hub (DxD) and A*STAR will continue to perform further clinical validation with Singapore based hospital provider; Aptorum Innovations will facilitate further clinical validation with other locations including but not limited to Australia-based Talem Medical Group, Raffles Medical Group (Hong Kong) and other future collaboration potentials.
Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented: “With the significant worldwide disruption caused by the COVID19 pandemic and the current global focus on antimicrobial resistance, further to our recent joining with the BEAM alliance2, Aptorum Group expands its potential infectious disease liquid biopsy diagnostics capabilities in synergy with its current infectious disease platform (for example, the leading Staphylococcus aureus drug program ALS-4) and supports worldwide antimicrobial stewardship policies (ASPs). Bacteremia infections, for example, alone cause nearly 500,000 hospitalizations in the United States annually and account for 11 percent of intensive care unit (ICU) admissions with over $20.3 billion in aggregate cost3. Mortality associated with these infections is extremely high and can range anywhere from 25 percent to 80 percent4. In accordance with Infectious Diseases Society of America’s (IDSA) policy paper5, many patients with suspected infections receive empiric antimicrobial therapy rather than appropriate specialized therapy dictated by rapid identification of the infectious agent and as a result, leading to nearly 50% of inappropriate overuse of our small inventory of antimicrobials challenged by rising levels of antimicrobial resistance6. Current blood culture-based testing is often inaccurate and time-consuming (up to 3 days on average7) resulting in unnecessary patient morbidity and increased risks of mortality. Moreover, current broad spectrum molecular diagnostics are often too cost-benefit prohibitive8 and therefore are not adopted as the first line of diagnostics for healthcare providers – with our technology we target to reduce end user costs by over 60% (or more) relative to current service provider average prices. With the forecast global molecular diagnostics market size to reach over US$13.8billion by 2025, the need to integrate broad-spectrum and affordable rapid molecular diagnostics into day-to-day clinical care and public health has never been greater and the RPIDD technology is being developed to target the improvement of clinical outcomes for patients and tracking of unknown pathogens in a cost-effective manner for our healthcare system9. Aptorum Group, through its subsidiary Aptorum Innovations, intends to commercialize RPIDD through the future set up of proprietary clinical microbiology laboratories as part of our dedicated focus to counter worldwide infectious disease related issues and will explore future collaborations with, for example, other NGS platforms to support this endeavour. It is with great pleasure to announce our planned global diagnostics expansion via Singapore’s robust healthcare ecosystems, such as this cooperation with A*STAR whose experienced and innovative molecular engineering team we are confident will help disrupt the global infectious disease liquid biopsy diagnostics market and further promote molecular-based diagnostics as the first line of defence for infectious diseases.”
About The Rapid Pathogen Identification and Detection Diagnostics Technology (RPIDD)
RPIDD is an innovative liquid biopsy-driven rapid pathogen molecular diagnostics technology with proprietary and patented technologies being developed to deplete host DNA and enrich pathogenic DNA / RNA for analysis through harnessing the power of Next-Generation Sequencing platforms (such as Illumina’s sequencing platforms) and proprietary artificial intelligence-based software analytics to rapidly identify and detect in blood over a potential targeted 1000+ viruses, bacteria, fungi and parasites present through its genome composition and other unknown pathogens. RPIDD has been and continues to be validated in human samples and so far, such testing has been able to detect pathogens – ranging from bacteria, fungi and viruses in an unbiased manner. RPIDD is currently under optimization for upcoming planned validations in collaboration with a number of healthcare providers in Singapore and other jurisdictions before it may be commercialized.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through programs such as the systematic screening of existing approved drug molecules and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. Aptorum also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020.
As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.
This press release is provided “as is” without any representation or warranty of any kind.
3 Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2011;29:S109–S116. Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer: HCUP Statistical Brief #160. 2013. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.pdf Accessed June 23, 2015.
Aptorum Group Limited
Investor Relations Department:
Tel: +44 20 80929299
Redchip – Financial Communications United States
+1 407 491 4498
Actifin – Financial Communications Europe
+33 1 56 88 11 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Successful Certification of Kalray’s Smart Storage Adapter19.10.2020 19:00:00 EEST | Press release
Kalray (Paris:ALKAL) (Euronext Growth Paris: FR0010722819 – ALKAL), a pioneer in processors for new intelligent systems, today announced that its K200™ Coolidge™ based smart storage adapter solution has been certified for NVM ExpressTM over Fabrics (NVMe-oF) with TCP (NVMe™/TCP) protocol by the NVM Express organization through the University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent testing provider of standard conformance solutions and multi-vendor interoperability. Data Centers are undergoing a very important revolution with rapidly evolving network architectures and technologies. This is mainly due to the explosion of usages, the surge of data to be processed and the resulting exponential growth of the number of machines to be managed to support this growth. Until now, storage has been one major bottleneck of this expansion. The introduction of flash memory-based SDD (Solid-State Drive) with hyper-fast communication protocols such as NVMe™/TCP, offers a
Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients19.10.2020 18:29:00 EEST | Press release
Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. The updated PI includes immunogenicity data from the NuProtect study in previously untreated patients (PUPs). FVIII inhibitor development is the most serious treatment complication in previously untreated patients (PUPs) with severe haemophilia A. The development of inhibitors against exogenous FVIII can reduce the effectiveness of treatment and negatively impact a patient's long-term joint health and quality of life. Minimising the risk of inhibitor development is therefore a key consideration in treatment decisions for PUPs. The updated NUWIQ® PI includes data from the NuProtect study, which was the largest prospective study of a single FVIII product in true PUPs. Patients rec
Activist Malala Yousafzai and American Football Coach Katie Sowers Among Others to Headline PMI® Virtual Experience Series19.10.2020 16:00:00 EEST | Press release
Project Management Institute (PMI), the world's leading association for the project management profession, is providing professionals around the world the opportunity to join three more groundbreaking Virtual Experience Series events on 20 October 2020, 12 November 2020, and 9 December 2020. Hosted by journalist, television host, and executive producer Tamron Hall, these online events connect attendees to hear unique perspectives and lessons-learned from inspiring thought leaders and experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005488/en/ Hear Pakistani education activist and the youngest Nobel Prize laureate, Malala Yousafzai, speak about advancing female education and enabling women’s leadership globally. (Photo: Business Wire) “By bringing these topics to light and providing them a global stage, we can embolden people to embrace change and lean in to new opportunities,” said Sunil Prashara, president and
Bentley Systems announces Executive Appointments of Nicholas Cumins (Chief Product Officer), Katriona Lord-Levins (Chief Success Officer), and Chris Bradshaw (Chief Marketing Officer)19.10.2020 16:00:00 EEST | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, announced today, following the initial public offering of its stock on September 23, the company’s successful recruitment for three significant operating positions. All three new executives are presently in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005179/en/ Nicholas Cumins, Chief Product Officer, Bentley Systems (Photo: Business Wire) Greg Bentley said, “While Bentley Systems accomplished much throughout our 36 years of growth as a privately-held company, and I am proud of our executive talent depth, we obviously could not internally develop public company experience. The principal purpose of our IPO last month was to assure market liquidity for our colleagues, and especially executive shareholders, in advance of many anticipated retirements. In turn, for the executive opportunities accordingly created, our new h
FutureOn Secures Investment from the Bentley Acceleration Fund for Oil & Gas Digitalization19.10.2020 16:00:00 EEST | Press release
FutureOn, the fast-growing Norwegian software company that works with an expanding portfolio of global energy companies, announced today that it has secured an investment from the Bentley Acceleration Fund and established a strategic partnership with US-based Bentley Systems to accelerate the digitalization of the oil and gas industry. FutureOn and Bentley Systems (Nasdaq: BSY), the infrastructure engineering software company, will combine FutureOn’s award-winning field design application (FieldAP) and its API-centric collaboration platform (FieldTwin) with Bentley’s iTwin platform to provide customers a next-generation digital twin solution capable of driving design methodologies in upstream project development for the next decade. Both FutureOn and Bentley platforms use open web standards to facilitate complex integration and customization, and the combined offerings are already being implemented in exploration and production workflows. “This is a significant milestone for FutureOn w
Alexis Nasard to Join Kantar as CEO19.10.2020 14:20:00 EEST | Press release
Kantar, the world’s leading data, insights and consulting company, announces the appointment of Alexis Nasard as Chief Executive Officer, effective 30 December 2020. Alexis Nasard joins Kantar with almost 30 years’ experience in the FMCG and retail world. Most recently Mr Nasard is currently CEO of Bata. Prior to that, Alexis spent six years at Heineken, culminating in the position of President of Western Europe Business and Global Chief Marketing Officer. Earlier, he worked for 17 years with Procter & Gamble, in a variety of marketing and general management roles. Mr Nasard holds an MBA degree from UC Berkeley’s Haas School of Business, USA and an MS/BS degree in Civil Engineering from Saint Joseph University, Lebanon. Of his appointment, Mr Nasard said “Throughout my career Kantar has been a trusted advisor. Kantar’s data, insights and advice informed many of the strategies, as well as communication and commercial plans my teams and I led. As much as I understand Kantar’s heritage an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom